The impact of neutralizing antibodies on the risk of disease worsening in interferon β-treated relapsing multiple sclerosis: a 5 year post-marketing study.
Paolicelli D, D'Onghia M, Pellegrini F, Direnzo V, Iaffaldano P, Lavolpe V, Trojano M
J Neurol. 2013 Feb 17. Epub 2013 Feb 17. PMID: 23417273.Abstract